Sanofi Ventures
Investor profile
CorporateVenture capital
Sanofi Ventures has backed 10 European tech companies across 12 funding rounds between 2020 and 2026, joining rounds totalling €1.1B. Most active in Healthtech and Transportation. Data as of Nov 2026.
Also recorded as: Sanofi
Deals
12
distinct rounds
Companies
10
backed
Active span
2020–2026
7 yrs
Total round €
€1.1B
sum of rounds joined
Deals by year
distinct rounds / yearSanofi Ventures — deals by year — interactive chart.
Data table
| Sanofi Ventures — deals by year | |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Top sectors
by dealsSanofi Ventures — top sectors — interactive chart.
Data table
| Sanofi Ventures — top sectors | |
|---|---|
| Healthtech | 11 |
| Transportation | 1 |
Stages
by dealsSanofi Ventures — stages — interactive chart.
Data table
| Sanofi Ventures — stages | |
|---|---|
| Other | 5 |
| Series B | 3 |
| Series C | 2 |
| Seed | 1 |
| Series D+ | 1 |
Countries
by dealsSanofi Ventures — countries — interactive chart.
Data table
| Sanofi Ventures — countries | |
|---|---|
| France | 4 |
| UK | 3 |
| Denmark | 2 |
| Belgium | 1 |
| Netherlands | 1 |
| Spain | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Novo Holdings3
- Adjuvant Capital2
- Asabys Partners2
- EQT Life Sciences2
- GV2
- Industrifonden2
- LF Investment2
- Northpond Ventures2
- Oxford Science Enterprises2
- Sunstone Life Science Ventures2
- Syncona Partners2
- Trill Impact Ventures2
- Wellington Partners2
- Bain Capital Life Sciences1
- Bpifrance1
- British Business Bank1
- CMA CGM Ventures1
- Forbion1
- Gilde Healthcare1
- Invus1
- Janus Henderson Investors1
- Jefferson Life Sciences1
- Khosla Ventures1
- New Enterprise Associates1
- Novartis Venture Fund1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| OMass Therapeutics | UK | 2 | €362M |
| Owkin | France | 1 | €159M |
| Aqemia | France | 1 | €129M |
| SpliceBio | Spain | 1 | €118M |
| Agomab Therapeutics | Belgium | 1 | €83M |
| MinervaX | Denmark | 2 | €76M |
| Lava Therapeutics | Netherlands | 1 | €70M |
| Gyroscope Therapeutics | UK | 1 | €35M |
| Eligo Bioscience | France | 1 | €28M |
| Livmed’s | France | 1 | €5.0M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Owkin | Other | €159M | 2021-11 |
| Aqemia | Other | €129M | 2023-12 |
| SpliceBio | Series B | €118M | 2025-06 |
| OMass Therapeutics | Series B | €90M | 2022-04 |
| Agomab Therapeutics | Series D+ | €83M | 2024-10 |
| Lava Therapeutics | Series C | €70M | 2020-09 |
| MinervaX | Other | €54M | 2023-10 |
| Gyroscope Therapeutics | Other | €35M | 2021-11 |
| Eligo Bioscience | Series B | €28M | 2023-12 |
| MinervaX | Other | €22M | 2022-12 |